Healthcare Industry News: Transdermal
News Release - October 10, 2007
NuPathe Inc. Names Jerry McLaughlin as Vice President of Commercial OperationsPositions NuPathe to Advance NP101 SmartRelief(TM) Transdermal Drug Delivery Technology Toward Commercialization
CONSHOHOCKEN, Pa.--(HSMN NewsFeed)--NuPathe Inc. a privately held specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases, today announced that Jerry McLaughlin has been appointed Vice President of Commercial Operations. Mr. McLaughlin has more than 17 years of specialty pharmaceutical industry experience in the U.S. and globally in new products planning, brand marketing, and sales. Mr. McLaughlin has launched twelve brands in a variety of therapeutic categories and has a strong background in strategic planning and commercial assessment.
"Jerry's extensive commercial, marketing and business development expertise will be extremely valuable as NuPathe continues to advance toward late stage development and product commercialization opportunities in the years ahead," said Jane Hollingsworth, chief executive officer of NuPathe. "Hiring Jerry is a big step in bringing NuPathe one step closer to commercializing its NP101 SmartRelief(TM), a novel treatment for acute migraine." NuPathe anticipates starting the Phase III clinical trial for NP101 by the end of 2007.
Mr. McLaughlin spent the past six years in increasingly responsible positions at Endo Pharmaceuticals (Nasdaq:ENDP ). In his last position as Senior Director of Strategic Marketing, Mr. McLaughlin led the company's portfolio planning efforts as well as commercial assessments and licensing and acquisition opportunities in Neurology, Supportive Care Oncology and Pain Management. Prior to joining Endo, Mr. McLaughlin spent eleven years at Merck & Co., Inc. (NYSE:MRK ) where he started as a sales representative and worked his way up to Associate Director of Marketing in the Worldwide Human Health Division of Merck & Co., Inc. In that capacity, he was responsible for developing global business and product lifecycle plans for Merck products. Mr. McLaughlin has a BA degree from Dickinson College and an MBA from Villanova University.
Migraine is a widespread, chronic condition that affects approximately 28 million Americans. The primary symptoms include intense and disabling headache, acute sensitivity to light and sound, nausea, and aura. Some experts estimate that the loss of productivity associated with migraine costs the economy between $13 and $17 billion each year. (1)
NuPathe specializes in the development of therapeutics for the treatment of neurological and psychiatric disorders including migraine, Parkinson's disease and schizophrenia. NuPathe's lead product, NP101, uses SmartRelief(TM), the company's novel, Transdermal patch technology, to deliver sumatriptan, a widely-used therapy for the treatment of acute migraine. Pending regulatory review and approval, NP101 would be the first ever migraine treatment based on a Transdermal patch delivery. Phase I clinical results for NP101 have thus far demonstrated rapid delivery of migraine medication and improved pharmacokinetics compared to current standard of care.
For additional information, visit www.nupathe.com.
(1) Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159(8):813-818.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.